HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HORTON, W. A. Articles by BRODY, J. A. Search for Related Content PubMed PubMed Citation Articles by HORTON, W. A. Articles by BRODY, J. A.

Familial motor neuron disease

Evidence for at least three different types

From the Section on Neurogenetics, Infectious Disease Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (Drs. Horton and Eldridge), and the Atomic Bomb Casualty Commission, Hijiyama Park 5-2, Hiroshima, Japan 730 (Dr. Brody).

Based on a clinical, pathologic, and genetic study of 14 families, at least three types of familial motor neuron disease can be distinguished, all apparently of autosomal dominant transmission. The first is characterized by rapid, progressive loss of motor function with predominantly lower motor neuron manifestations and a course lasting less than 5 years. Pathologic changes are limited to the anterior horn cells and pyramidal tracts. The second type is clinically identical to the first, but at autopsy additional changes are found in the posterior columns, Clarke's column, and spinocerebellar tracts. The third type is characterized by a much longer survival usually beyond 10 and after more than 20 years in affected family members but is otherwise similar to the second type.

Dr. Eldridge's address is Section on Neurogenetics, Infectious Disease Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD 20014.

Received for publication September 22, 1975.

This article has been cited by other articles:

				D. S. Howland, J. Liu, Y. She, B. Goad, N. J. Maragakis, B. Kim, J. Erickson, J. Kulik, L. DeVito, G. Psaltis, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) PNAS, January 24, 2002; (2002) 32539299. [Abstract] [Full Text] [PDF]

				D W Gross, A H Rajput, and M Yeung Distal hereditary upper limb muscular atrophy J. Neurol. Neurosurg. Psychiatry, February 1, 1998; 64(2): 217 - 220. [Abstract] [Full Text] [PDF]

				C. S. Payne and A. D. Roses The Molecular Genetic Revolution: Its Impact on Clinical Neurology Arch Neurol, December 1, 1988; 45(12): 1366 - 1376. [Abstract] [PDF]

				S. Gimenez-Roldan and A. Esteban Prognosis in Hereditary Amyotrophic Lateral Sclerosis Arch Neurol, November 1, 1977; 34(11): 706 - 708. [Abstract] [PDF]

				D. S. Howland, J. Liu, Y. She, B. Goad, N. J. Maragakis, B. Kim, J. Erickson, J. Kulik, L. DeVito, G. Psaltis, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) PNAS, February 5, 2002; 99(3): 1604 - 1609. [Abstract] [Full Text] [PDF]